CG Oncology
Market cap $7.05B 89.3M shares (10-Q, Nov 4, 2026) × $78.94 close Nov 17, 2026
Most recent annual filing: 2026-02-15
- CORE-008 Cohort CX / BOND-003Dec 2026CORE-008 Cohort CX / BOND-003, Dec 2026, notable
- BCG-unresponsive BLA filingMar 2027BCG-unresponsive BLA filing, Mar 2027, notable
- Intermediate-risk / HG Ta NMIBC2Q 2027Intermediate-risk / HG Ta NMIBC, 2Q 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (1 active programs)
Capital (as filed)
- Cash
- $28.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $956M Sep 30, 2026
- Operating cash flow
- −$47.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $985M cash, runway through 2029 per the update of Nov 6, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-08-06 424B5 · At-the-market program up to $500M
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (9)
- 2026-11-17 UPDATE: CG Oncology (CGON) - The House Is Fireproofed 🔒 Paid
- 2026-11-07 UPDATE: CG Oncology (CGON) - The Readout Gets a Month 🔒 Paid
- 2026-10-13 UPDATE: CG Oncology (CGON) - The Commercial Chair Is Filled 🔒 Paid
- 2026-08-07 UPDATE: CG Oncology (CGON) — The ATM Reloads at $72 🔒 Paid
- 2026-05-26 UPDATE: CG Oncology (CGON) — The COO Walks, the CEO Doubles Up 🔒 Paid
- 2026-05-16 UPDATE: CG Oncology (CGON) — The Gem Combo Clears the Bar 🔒 Paid
- 2026-05-09 UPDATE: CG Oncology (CGON) — Q1 2026 Status Check 🔒 Paid
- 2026-02-28 UPDATE: CG Oncology (CGON) - EoY Update 🔒 Paid
- 2026-01-23 CG Oncology (CGON): Scientific Deep Dive for Creto and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (9 calls)
Every verdict Biotech Distilled has published on CG Oncology, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-23 Buy core CG Oncology (CGON): Scientific Deep Dive for Creto and Pipeline Products Best-in-class Phase 3 data (75.5% CR), clean safety profile (0% Grade 3+ TRAEs), fortress cash position, resolved legal overhang, and strong M&A appeal make CGON a high-conviction buy on pullbacks.
- 2026-02-28 Buy core UPDATE: CG Oncology (CGON) - EoY Update Balance sheet transformed to near-$1B fortress after aggressive ATM execution, financing overhang thesis dead, and core thesis strengthened ahead of PIVOT-006 and BLA submission.
- 2026-05-09 Buy core UPDATE: CG Oncology (CGON) — Q1 2026 Status Check ATM fully drawn at $57.56 average closing the dilution overhang, BLA on defined Q4 2026 path, and two near-term catalysts (AUA May 16 combo data and PIVOT-006 topline) support maintaining the position.
- 2026-05-16 Buy core UPDATE: CG Oncology (CGON) — The Gem Combo Clears the Bar CORE-008 Cohort CX posted 85.7%/92.3% CR with 0% Grade 3+ TRAEs, validating the combination platform and reducing the 'creatures of habit' launch risk, while PIVOT-006 remains the next major catalyst.
- 2026-05-26 Buy core UPDATE: CG Oncology (CGON) — The COO Walks, the CEO Doubles Up Clinical platform and balance sheet remain intact despite COO departure; 7.5% drawdown into clean combo data may be an attractive entry, though launch-readiness risk has increased with the CCO seat open heading into PIVOT-006.
- 2026-08-07 Buy core UPDATE: CG Oncology (CGON) — The ATM Reloads at $72 ANI post-trial motions denied closing the legal overhang, BOND-003 peer-reviewed in The Lancet with stronger durability metrics, and PIVOT-006 topline imminent, though a new $500M ATM at $72 and accelerating burn are partial offsets.
- 2026-10-13 Buy core UPDATE: CG Oncology (CGON) - The Commercial Chair Is Filled CCO vacancy filled by Isabel Kalofonos, a multi-launch specialist oncology veteran, closing the launch-readiness gap opened by the COO's departure, while clinical platform and legal picture remain intact.
- 2026-11-07 Buy core UPDATE: CG Oncology (CGON) - The Readout Gets a Month PIVOT-006 topline pinned to November 2026, Q3 burn lighter than modeled, fortress balance sheet intact, though ANI appeal is now live at Delaware Supreme Court and the $500M ATM sits above the tape.
- 2026-11-17 Buy core UPDATE: CG Oncology (CGON) - The House Is Fireproofed PIVOT-006 hit its primary endpoint with HR 0.32 (p<0.0001), a 68% recurrence risk reduction in a randomized Phase 3, validating the backbone therapy framing and supporting a re-rating, with first BLA slipping one quarter to March 2027 for a broader label.
- Long call · opened Jan 23, 2026 at $53.81 · +46.7% vs XBI +13.5% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“To incorporate the additional data, we now expect to complete the submission before the end of March 2027.”
matched to PIVOT-006 · topline data
-
-
-
“PIVOT-006 (intermediate-risk and high-grade Ta ≤ 3cm NMIBC): Phase 3 topline data November 2026”
matched to PIVOT-006 · topline data · since happened Nov 16, 2026
-
-
-
“This trial served as the basis for our Biologics License Application (BLA) submission for our initial indication to the U.S. Food and Drug Administration (FDA), which we expect to complete in the fourth quarter of 2026.”
matched to Creto · readout other
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (24)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 8, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleasePIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)→ BD updateSummary on the 8-K
- Nov 16, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updatePIVOT-006 just delivered a hazard ratio of 0.32 (p<0.0001) in a randomized Phase 3 against surveillance — a 68% cut in recurrence risk with zero Grade 3+ TRAEs. The salvage-therapy story just became the backbone-therapy story.
- Nov 6, 2026ReleaseCG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates→ BD updateSummary on the 8-K
- Nov 6, 20268-KCurrent report: results of operations · EX-99.1→ BD updatePIVOT-006 Phase 3 topline is now "November 2026" — the Market Expander readout is weeks, not quarters, away — while ANI has escalated to the Delaware Supreme Court, introducing a wrinkle I called "mostly resolved." The stock surged 17.3% on today's Q3 print.
- Nov 6, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 13, 2026ReleaseCG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer→ BD updateCG Oncology has filled the Chief Commercial Officer vacancy with Isabel Kalofonos — a two-time CCO with successful launches at Crinetics (PALSONIFY) and ImmunoGen (ELAHERE) — closing the launch-readiness footnote the author flagged as the #2 watch item since May.
- Sep 2, 2026ReleaseCG Oncology to Present at Upcoming Investor Conferences in September
- Aug 6, 2026ReleaseCG Oncology Reports Second Quarter 2026 Financial Results and Provides Business UpdatesBD extracted 1 program update from this document → CGON pipeline
- Aug 6, 20268-KCurrent report: results of operations, other events · EX-99.1
- Aug 6, 2026424B5Prospectus supplement (offering)
- Aug 6, 202610-QQuarterly report
- Jul 27, 2026ReleaseCG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet OncologyBD extracted 1 program update from this document → CGON pipeline
- Jun 8, 20268-KCurrent report: shareholder vote
- May 28, 2026ReleaseCG Oncology to Present at Upcoming Investor Conferences in June
- May 26, 20268-KCurrent report: officer / director change
- May 19, 2026ReleaseSUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
- May 15, 2026ReleaseCG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
- May 11, 2026ReleaseCG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
- May 8, 2026ReleaseCG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
- May 8, 20268-KCurrent report: results of operations · EX-99.1
- May 8, 202610-QQuarterly report
- Apr 24, 2026DEFA14AProxy soliciting material
- Apr 24, 2026DEF 14AProxy statement
- Apr 13, 20268-KCurrent report: officer / director change
8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Jul 27, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 24, 2026ARSAnnual report to shareholders
- Mar 26, 2026SCHEDULE 13G/A13G amendment